Gb Sciences

As a part of their Exclusive Licensing Deal, EndoPure Life Sciences will finance and sponsor first-in-human clinical trials, which help to advance GB Sciences’ cannabinoid-based products globally.

GB Sciences’ Licensing Deal with Endopure Life Sciences will also include Rights to Develop and Market GB Sciences’ Cannabinoid-based Treatments for a Suite of Neurological Disorders

Tune in this Sunday, Dec. 17, at 5:30 p.m. ET on the Fox Business Network to learn about Gb Sciences’ cannabinoid-based medicine for the treatment of Parkinson’s disease.

The Parkinson's disease market is expected to grow to $12.8 billion by 2028.

According to Statista, China has the second largest pharmaceutical market in the world and plant-based medicines are very well accepted, which makes China a potential target market for Gb Sciences.

Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2023 and key developments from 2022

Gb Sciences' innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections.

As mental health disorders increasingly impact global populations, Gb Sciences is developing psychotropic but non-psychedelic treatments for anxiety and depression that compete with the emerging billion-dollar psychedelic companies.

As published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm's sponsored research used co-cultured human, primary immune cells as a model to evaluate the ability of selected Cannabis constituents to decrease inflammation.

At the Annual Summit, Dr. Andrea Small-Howard is presenting a Keynote Address that includes data from case studies demonstrating the utility of Gb Sciences' proprietary PhAROS drug discovery platform.

Gb Sciences' anxiety formulations were previously identified using the company's AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the National Research Council of Canada.

Dr. Andrea Small-Howard discusses the company's novel process for developing disease-specific, cannabinoid-based therapeutics.

As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm's sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for the treatment of Parkinson's disease symptoms

Gb Sciences is focusing considerable resources on bringing its lead Parkinson's disease formulations to the clinic with promising results; plus, new data validating the efficacy of their novel anxiety formulations and demonstrating the improved stability of their oral nanoparticle-encapsulated chronic pain formulations add value to their drug development pipeline.

As digitization becomes a necessity in the life sciences industry, Gb Sciences proves it's already ahead of the curve with its own revolutionary technology.

As digitization becomes a necessity in the life sciences industry, Gb Sciences proves it's already ahead of the curve with its own revolutionary technology.

Dr. Andrea Small-Howard explains that Gb Sciences' multicomponent Parkinson's disease therapeutic addresses this multi-factorial neurodegenerative condition using a combination of cannabinoids that are more effective when used together than singularly, as demonstrated in an animal model of the disease.

President and Chief Science Officer Dr. Andrea Small-Howard demonstrates the platform's utility for predicting novel plant-inspired drug candidates and describes its role in Gb Sciences' future successes

President and Chief Science Officer Dr. Andrea Small-Howard stressed the importance of developing their innovative, plant-inspired formulations as a potentially safer alternative to existing opioid-based pain medications.

Plant-inspired biopharmaceutical company signs leading contract research organization to help with a go-to-market strategy for its cannabinoid-containing therapy for COVID-related cytokine release syndrome.

Biopharmaceutical research company's plant-inspired formulations entering final stages before first-in-human clinical trials

On March 25, the University of Seville, Chaminade University, and Gb Sciences co-published the results from Gb Sciences-sponsored study in the International Journal of Pharmaceutics. Gb Sciences' proprietary, time-released, oral nanoparticle technology improved the efficacy of cannabis-based terpenes in modulating a known pain receptor in this study.

Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021

Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021

This new patent covers receptor-targeted formulations for the treatment of cardiac hypertrophy, TRPV1-receptor-associated hearing loss and urinary cystitis.

Gb Sciences' collaboration with MSU has received media coverage across the country, starting with an interview from WLNS-TV in Lansing, Michigan, and interviews with Gb Sciences in the magazines 'Cannabis Business Times' and 'Hemp Grower'

The sale will accelerate the development of Gb Sciences' proprietary Parkinson's disease and COVID-related Cytokine-Release Syndrome therapies

Biopharmaceutical research company leverages positive data on its cannabinoid-containing mixtures to develop new cytokine release syndrome therapies

Biopharmaceutical research company pursues faster route for drug discovery using PhAROS™, Gb Sciences' AI-enabled drug discovery platform, and through efficiency in their drug development pipeline leveraging strong relationships

The biopharma technology company's AI-driven PhAROS™ platform has identified novel, plant-inspired formulations that will be tested using preclinical Zebrafish models at the National Research Council of Canada.

Based on a recently completed preclinical study performed at Michigan State University, Gb Sciences' preclinical data supports further development of their novel cannabinoid-containing complex mixtures as anti-inflammatory therapies for hyperinflammatory conditions associated with COVID-19 and other life-threatening inflammatory conditions.

Highlighting Gb Sciences' Development of Plant-Inspired Therapies for COVID-related Cytokine Release Syndrome, Chronic Pain, and Parkinson's Disease during the Healthcare & Biotech Track starting Monday, September 13.

GB Sciences used PhAROS™, their novel AI-accelerated drug discovery platform, to identify and pre-validate optimized therapeutic mixtures for the treatment of anxiety, depression, and pain inspired by a family of pepper plants used in traditional medicines around the world.

Biotech innovator GB Sciences has launched a drug discovery platform using AI technology that can identify and predict the efficacy of combinations of novel active ingredients from plants.

Herman will bring his experience as an investor in undervalued growth companies to this role as Advisory Director

The UWC also retains John Poss as Chairman and CEO of GB Sciences, Inc.

Dr. Andrea Small-Howard will be speaking as a part of the live Pain, Migraine & Addiction Panel on April 29 at 11:50 a.m. EDT, and she will be presenting the company during the 20-minute SPOTLIGHT SHOWCASE.

Purisys will supply ultra-high purity cannabinoids for use in GB Sciences' cannabinoid-containing, optimized therapeutic mixtures (OTM).

GBS' newest proprietary drug discovery platform uses data analytics and machine learning to gain valuable predictive insights into the likely efficacy of novel plant-derived therapeutics. This unique ability allows researchers to reduce the time and money required for novel, plant-based combination drugs to get to market. This is the intersection of hard science, plant-based medicine, and solid business practices.

GB Sciences and their Spanish research partners at the Universidad de Sevilla (USE) have created terpene-containing nanoparticles. These first of their kind nanoparticles are central to GB Sciences' time-released pain formulations that are currently in animal trials at the NRC Canada, in preparation for an IND-filing for a US FDA-registered clinical trial.

If successful, data from this preclinical study would be used as part of the support for an Independent New Drug (IND)-filing with the US Food and Drug Administration (FDA) for the use of GBS' Cannabinoid Containing Complex Mixtures (CCCM™) to treat the potentially-fatal Cytokine Release Syndrome associated with COVID-19 and other dangerous hyperinflammatory conditions.

This is the third U.S. patent awarded to GBS's disease-specific Cannabinoid-Containing Complex Mixtures (CCCM™), which further validates GB Sciences' drug discovery platform and strengthens its intellectual property patent portfolio